title: HER2-positive gastric cancer.
abstract: Human epidermal growth factor receptor 2 (HER2) is involved in the pathogenesis and poor outcomes of several types of cancer, including advanced gastric and gastroesophageal junction cancer. Molecular-targeted drugs, such as trastuzumab, which prolong overall survival and progression-free survival in HER2-positive breast cancer, may also be beneficial in patients with HER2-positive gastric cancer. Several studies have examined this possibility, such as the Trastuzumab for Gastric Cancer trial. In this context, the first part of this review provides an update on our knowledge of HER2 in breast and gastric cancer, including the detection and prognostic relevance of HER2 in gastric cancer. The second part of the review discusses the results of pivotal clinical trials that examined the potential for using trastuzumab to treat this disease. This section also summarizes the trials that have been conducted or that are underway to determine the optimal uses of trastuzumab in gastric cancer, including its use as monotherapy and continuation beyond disease progression. The final section discusses the future prospects of other anti-HER2 drugs, including lapatinib, trastuzumab emtansine, and pertuzumab, for the treatment of HER2-positive gastric cancer. The introduction of trastuzumab led to the establishment of a new disease entity, "HER2-positive gastric cancer," similar to HER2-positive breast cancer. It is expected that more anti-HER2 drugs will be developed and introduced into clinical practice to treat HER2-positive cancers, including gastric cancer.
authors.affiliation: Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae-ku, Kawasaki, Kanagawa, Japan, n.boku@marianna-u.ac.jp.
authors.forename: Narikazu
authors.initials: N
authors.lastname: Boku
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000378:metabolism; D005260:Female; D006801:Humans; D000077341:Lapatinib; D008453:Maytansine / Q000031:analogs & derivatives / Q000494:pharmacology; D058990:Molecular Targeted Therapy / Q000379:methods*; D011379:Prognosis; D011799:Quinazolines / Q000494:pharmacology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000601:surgery; D000068878:Trastuzumab
chemical_list: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077341:Lapatinib; D008453:Maytansine; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human; C485206:pertuzumab
references.citation: Dis Esophagus. 2013 Apr;26(3):299-304
references.pmid: 22676551
references.citation: Hum Pathol. 2007 Sep;38(9):1386-93
references.pmid: 17555797
references.citation: Clin Breast Cancer. 2003 Jun;4(2):120-5
references.pmid: 12864940
references.citation: Oncogene. 2003 Sep 29;22(42):6570-8
references.pmid: 14528282
references.citation: Lancet Oncol. 2013 Jan;14(1):29-37
references.pmid: 23168366
references.citation: Lancet. 2010 Aug 28;376(9742):687-97
references.pmid: 20728210
references.citation: Histopathology. 2008 Jun;52(7):797-805
references.pmid: 18422971
references.citation: Oncol Rep. 2006 Jan;15(1):65-71
references.pmid: 16328035
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: Eur J Cancer. 2011 Oct;47(15):2306-14
references.pmid: 21742485
references.citation: Ann Oncol. 2012 Oct;23(10):2656-2662
references.pmid: 22689179
references.citation: J Clin Oncol. 2009 Apr 20;27(12):1999-2006
references.pmid: 19289619
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1124-30
references.pmid: 20124187
references.citation: Ann Oncol. 2001;12 Suppl 1:S9-13
references.pmid: 11521729
references.citation: J Hematol Oncol. 2010 Sep 09;3:31
references.pmid: 20828403
references.citation: Lancet Oncol. 2011 Mar;12(3):236-44
references.pmid: 21354370
references.citation: Proc Natl Acad Sci U S A. 1985 Oct;82(19):6497-501
references.pmid: 2995967
references.citation: Nature. 1986 Jan 16-22;319(6050):230-4
references.pmid: 3003577
references.citation: World J Gastroenterol. 2012 May 21;18(19):2402-7
references.pmid: 22654433
references.citation: Anticancer Res. 2012 Apr;32(4):1547-53
references.pmid: 22493400
references.citation: J Clin Pathol. 2010 Sep;63(9):839-42
references.pmid: 20696687
references.citation: Lancet. 2007 Jan 6;369(9555):29-36
references.pmid: 17208639
references.citation: Gastric Cancer. 2013 Apr;16(2):261-7
references.pmid: 22797858
references.citation: Breast Cancer. 2008;15(1):57-64
references.pmid: 18224396
references.citation: Cancer Res. 1989 Jun 1;49(11):3104-8
references.pmid: 2566377
references.citation: Ann Oncol. 2005 Feb;16(2):273-8
references.pmid: 15668283
references.citation: J Clin Oncol. 2012 May 1;30(13):1513-8
references.pmid: 22412140
references.citation: Histopathology. 2011 Nov;59(5):832-40
references.pmid: 22092394
references.citation: Curr Opin Mol Ther. 2010 Jun;12(3):350-60
references.pmid: 20521224
references.citation: Ann Oncol. 2001;12 Suppl 1:S3-8
references.pmid: 11521719
references.citation: Lancet. 1986 Apr 5;1(8484):765-7
references.pmid: 2870269
references.citation: Adv Anat Pathol. 2011 Jan;18(1):53-9
references.pmid: 21169738
references.citation: Zhonghua Zhong Liu Za Zhi. 2011 Sep;33(9):671-5
references.pmid: 22340047
references.citation: Mol Cell Biol. 1986 Mar;6(3):955-8
references.pmid: 2430175
references.citation: Jpn J Clin Oncol. 2011 May;41(5):709-12
references.pmid: 21355003
references.citation: J Clin Oncol. 2002 Feb 1;20(3):719-26
references.pmid: 11821453
references.citation: J Cancer. 2012;3:137-44
references.pmid: 22481979
references.citation: J Clin Oncol. 2010 Jan 1;28(1):92-8
references.pmid: 19933921
references.citation: Gastric Cancer. 2013 Jan;16(1):84-93
references.pmid: 22410801
references.citation: Cancer Chemother Pharmacol. 2010 Jul;66(2):269-76
references.pmid: 19904537
references.citation: N Engl J Med. 2012 Jan 12;366(2):109-19
references.pmid: 22149875
references.citation: Clin Cancer Res. 2008 May 15;14(10):3022-9
references.pmid: 18483367
references.citation: Breast Cancer Res. 2001;3(6):385-9
references.pmid: 11737890
references.citation: ScientificWorldJournal. 2012;2012:941259
references.pmid: 22645475
references.citation: J Clin Gastroenterol. 2012 Apr;46(4):e31-7
references.pmid: 22064554
references.citation: Oncogene. 1987;1(4):423-30
references.pmid: 3330785
references.citation: N Engl J Med. 2006 Dec 28;355(26):2733-43
references.pmid: 17192538
references.citation: J Clin Oncol. 2007 Jan 1;25(1):118-45
references.pmid: 17159189
references.citation: Lancet. 2010 Jan 30;375(9712):377-84
references.pmid: 20113825
references.citation: Lancet. 2012 Feb 18;379(9816):633-40
references.pmid: 22257673
references.citation: Dig Dis Sci. 2006 Aug;51(8):1371-9
references.pmid: 16868827
references.citation: Science. 1985 Dec 6;230(4730):1132-9
references.pmid: 2999974
references.citation: N Engl J Med. 2012 Nov 8;367(19):1783-91
references.pmid: 23020162
references.citation: N Engl J Med. 2006 Jul 6;355(1):11-20
references.pmid: 16822992
references.citation: Oncology. 2011;81(3-4):160-6
references.pmid: 22041972
references.citation: Mol Cancer Ther. 2009 Jul;8(7):1885-92
references.pmid: 19584234
references.citation: N Engl J Med. 2005 Oct 20;353(16):1659-72
references.pmid: 16236737
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: Clin Cancer Res. 2011 Oct 15;17(20):6437-47
references.pmid: 22003071
references.citation: Br J Cancer. 2009 Feb 10;100(3):487-93
references.pmid: 19156142
references.citation: World J Gastroenterol. 2011 Mar 21;17(11):1501-6
references.pmid: 21472111
references.citation: J Clin Oncol. 2010 Apr 20;28(12):2024-31
references.pmid: 20308670
references.citation: World J Surg Oncol. 2011 Sep 28;9:112
references.pmid: 21955806
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5838-47
references.pmid: 19884552
references.citation: N Engl J Med. 2005 Oct 20;353(16):1673-84
references.pmid: 16236738
references.citation: J Clin Pathol. 2012 Aug;65(8):751-7
references.pmid: 22569536
references.citation: J Clin Pathol. 2012 Mar;65(3):237-41
references.pmid: 22067088
references.citation: N Engl J Med. 2011 Oct 6;365(14):1273-83
references.pmid: 21991949
references.citation: J Gastrointest Surg. 2011 Mar;15(3):410-5
references.pmid: 21253876
references.citation: Int J Cancer. 2002 Apr 20;98(6):833-7
references.pmid: 11948459
references.citation: World J Gastroenterol. 2012 Jan 14;18(2):150-5
references.pmid: 22253521